Literature DB >> 18954744

Diffuse large B-cell lymphoma.

Jonathan W Friedberg1, Richard I Fisher.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) remains a curable lymphoma, with improved outcome resulting in large part from the incorporation of rituximab in standard regimens. The disease is heterogeneous clinically, morphologically, and molecularly. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy with rituximab remains a standard therapeutic approach for most patients who have DLBCL, it is anticipated that novel agents will be included in treatment regimens for many patients in the near future.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18954744      PMCID： PMC2593154          DOI： 10.1016/j.hoc.2008.07.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  38 in total

1.  Time trends of non-Hodgkin's lymphoma: are they real? What do they mean?

Authors:  T R Holford; T Zheng; S T Mayne; L A McKay
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

2.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

3.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

Review 4.  The epidemiology of non-Hodgkin's lymphoma.

Authors:  Susan G Fisher; Richard I Fisher
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

5.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

Authors:  Tarun Kewalramani; Andrew D Zelenetz; Stephen D Nimer; Carol Portlock; David Straus; Ariela Noy; Owen O'Connor; Daniel A Filippa; Julie Teruya-Feldstein; Alison Gencarelli; Jing Qin; Alyson Waxman; Joachim Yahalom; Craig H Moskowitz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

Review 6.  Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence.

Authors:  P Hartge; S S Devesa
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

7.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

8.  Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b.

Authors:  W H Wilson; D W Kingma; M Raffeld; R E Wittes; E S Jaffe
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

9.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Authors:  Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glass; Christian Rübe; Markus Loeffler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113
View more
  45 in total

Review 1.  Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

Authors:  Rene-Olivier Casasnovas; Michel Meignan; Alina Berriolo-Riedinger; Emmanuel Itti; Damien Huglo; Corinne Haioun; Franck Morschhauser
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

2.  Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

3.  Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.

Authors:  Deepti Chadalavada; Trinka W Adamson; John C Burnett; Robert W Chen; John J Rossi
Journal:  Comp Med       Date:  2014-06       Impact factor: 0.982

4.  Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Authors:  Meghan Bushway; Kelly A Cycon; Kathleen Mulvaney; Shawn P Murphy
Journal:  Immunogenetics       Date:  2009-12-19       Impact factor: 2.846

5.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.

Authors:  Stefano Monti; Bjoern Chapuy; Kunihiko Takeyama; Scott J Rodig; Yansheng Hao; Kelly T Yeda; Haig Inguilizian; Craig Mermel; Treeve Currie; Ahmet Dogan; Jeffery L Kutok; Rameen Beroukhim; Donna Neuberg; Thomas M Habermann; Gad Getz; Andrew L Kung; Todd R Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

6.  Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma.

Authors:  Changhoon Yoo; Dok Hyun Yoon; Jeong Eun Kim; Jungmin Jo; Seong Joon Park; Shin-Kyo Yoon; Yongchel Ahn; Shin Kim; Jooryung Huh; Dae Ho Lee; Cheolwon Suh
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

7.  Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.

Authors:  Mary Pulvino; Yue Liang; David Oleksyn; Michael DeRan; Elise Van Pelt; Joel Shapiro; Ignacio Sanz; Luojing Chen; Jiyong Zhao
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

8.  A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Authors:  Çağlar Çağlayan; Jordan S Goldstein; Turgay Ayer; Ashish Rai; Christopher R Flowers
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

9.  Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.

Authors:  Rajni Sinha; Loretta Nastoupil; Christopher R Flowers
Journal:  Blood Lymphat Cancer       Date:  2012-04-19

Review 10.  Next-generation prognostic assessment for diffuse large B-cell lymphoma.

Authors:  Ashley D Staton; Jean L Koff; Qiushi Chen; Turgay Ayer; Christopher R Flowers
Journal:  Future Oncol       Date:  2015-08-20       Impact factor: 3.404
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.